drugset / Trial / NCT04485052
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The study is to evaluate safety, tolerability and composite CR of IBI188 plus Demethylating Agents in acute myeloid leukemia
Timeline
- Start
- 2020-09-25
- Primary completion
- 2024-06-30
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Subcutaneous |
| Subject | Decitabine | Small molecule | — | Subcutaneous |
| Subject | IBI188 | Monoclonal antibody | — | Intravenous |